Forty patients with HER2-neu-negative advanced or metastatic GC received modified folinic acid, fluorouracil, and oxaliplatin (mFOLFOX), and andecaliximab (800 mg IV) every 2 weeks. Here, ERBB2 is linked to gastric cancer.